Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer.
EGFR
NSCLC
T790M mutation
TKI
TP53 mutation
cfDNA
pharmacokinetics
plasma conversion
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Oct 2020
29 Oct 2020
Historique:
received:
31
08
2020
revised:
19
10
2020
accepted:
21
10
2020
entrez:
3
11
2020
pubmed:
4
11
2020
medline:
4
11
2020
Statut:
epublish
Résumé
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with
Identifiants
pubmed: 33138052
pii: cancers12113179
doi: 10.3390/cancers12113179
pmc: PMC7692448
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : AstraZeneca
ID : 2604226313
Organisme : AstraZeneca
ID : 2604937054
Références
Crit Rev Oncol Hematol. 2020 Jul;151:102978
pubmed: 32428812
Lung Cancer. 2020 Mar;141:37-43
pubmed: 31945708
Genes Cancer. 2011 Apr;2(4):466-74
pubmed: 21779514
Transl Lung Cancer Res. 2020 Apr;9(2):239-245
pubmed: 32420063
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Lung Cancer. 2019 May;131:128-133
pubmed: 31027689
Lancet Oncol. 2020 May;21(5):e265-e279
pubmed: 32359502
J Clin Oncol. 2001 Jul 1;19(13):3267-79
pubmed: 11432895
Nat Rev Clin Oncol. 2018 Feb;15(2):81-94
pubmed: 29115304
Transl Lung Cancer Res. 2020 Jun;9(3):532-540
pubmed: 32676317
Br J Clin Pharmacol. 2017 Jun;83(6):1216-1226
pubmed: 28009438
Lung Cancer. 2018 Sep;123:70-75
pubmed: 30089598
JAMA Oncol. 2018 Nov 1;4(11):1527-1534
pubmed: 30073261
Clin Pharmacokinet. 2020 Jun 17;:
pubmed: 32557346
Onco Targets Ther. 2018 Apr 20;11:2217-2226
pubmed: 29720878
ESMO Open. 2018 Feb 8;3(2):e000292
pubmed: 29464111
Lung Cancer. 2020 Feb;140:46-54
pubmed: 31862577
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
J Clin Oncol. 2016 Oct 1;34(28):3375-82
pubmed: 27354477
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lung Cancer. 2019 Feb;128:33-39
pubmed: 30642450
Nat Cell Biol. 2013 Jan;15(1):2-8
pubmed: 23263379
Clin Pharmacol Ther. 2017 Nov;102(5):765-776
pubmed: 28699160
JCO Precis Oncol. 2018;2018:
pubmed: 30766968
Clin Cancer Res. 2018 Sep 15;24(18):4437-4443
pubmed: 29567812
Clin Pharmacol Ther. 2006 Aug;80(2):136-45
pubmed: 16890575
Oncologist. 2018 Oct;23(10):1199-1209
pubmed: 29650684
Ther Drug Monit. 2014 Jun;36(3):326-34
pubmed: 24305627
J Clin Oncol. 2018 Sep 10;36(26):2702-2709
pubmed: 30059262
Lung Cancer. 2019 May;131:86-89
pubmed: 31027703
Lung Cancer. 2017 Sep;111:23-29
pubmed: 28838393
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 15;1113:37-44
pubmed: 30889498
Oncotarget. 2020 Mar 17;11(11):982-991
pubmed: 32215186
J Pharm Biomed Anal. 2019 Aug 5;172:175-182
pubmed: 31051406
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2017 May 1;23(9):2195-2202
pubmed: 27780855
Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9
pubmed: 29462253
J Thorac Oncol. 2019 Feb;14(2):193-202
pubmed: 30391576
Ther Adv Med Oncol. 2019 Jan 04;11:1758835918818347
pubmed: 30643582
Transl Oncol. 2019 Nov;12(11):1425-1431
pubmed: 31401335
Cancer Manag Res. 2019 Jun 21;11:5665-5675
pubmed: 31417310